Amneal Pharmaceuticals (AMRX) Non Operating Income (2017 - 2026)

Amneal Pharmaceuticals' Non Operating Income history runs 10 years deep, the most recent figure standing at -$61.6 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 11991.12% year-over-year to -$61.6 million; the TTM figure through Mar 2026 stood at -$115.6 million (up 51.66% YoY), while the FY2025 annual figure was -$254.9 million, up 16.25% from the prior year.
• Non Operating Income was -$61.6 million for Q1 2026 at Amneal Pharmaceuticals, down from -$56.8 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $5.7 million in Q3 2022 to a low of -$91.1 million in Q4 2024.
• Historically, Non Operating Income has averaged -$32.4 million across 5 years, with a median of -$34.1 million in 2022.
• Biggest YoY gain for Non Operating Income was 109.28% in 2024; the steepest drop was 18101.2% in 2024.
• A 5-year view of Non Operating Income shows it stood at -$43.7 million in 2022, then surged by 103.72% to $1.6 million in 2023, then slumped by 5700.0% to -$91.1 million in 2024, then soared by 37.66% to -$56.8 million in 2025, then decreased by 8.45% to -$61.6 million in 2026.
• The last three Non Operating Income figures came in at -$61.6 million (Q1 2026), -$56.8 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.